GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » Capital Expenditure

Moberg Pharma AB (OSTO:MOB) Capital Expenditure : kr-88.24 Mil (TTM As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Moberg Pharma AB Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Moberg Pharma AB's cash flow for capital expenditures for the three months ended in Sep. 2024 was kr-20.41 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2024 was kr-88.24 Mil.

Moberg Pharma AB Capital Expenditure Historical Data

The historical data trend for Moberg Pharma AB's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Capital Expenditure Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -83.64 -33.49 -31.31 -68.07 -124.12

Moberg Pharma AB Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.64 -33.22 -17.82 -16.79 -20.41

Moberg Pharma AB Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-88.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » Capital Expenditure
Comparable Companies
OSTO:DICOT OSTO:ENZY OSTO:ORX OSTO:NANEXA OSTO:ERMA OSTO:TOL OSTO:VIVE XSAT:ACUC OSTO:NEWBRY OSTO:KLAR ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
MBGPF:USA MOBs:UK MB8:Germany
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Website
https://www.mobergpharma.se
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.